In vitro activity: Evatanepag (formerly known as CP-533536) is a potent and selective agonist of EP2 receptor prostaglandin E2 (PGE2). It induces local bone formation with EC50 of 0.3 nM. C

Kinase Assay: Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM. CP-533536 is a potent and selective EP2agonist. CP-533536 demonstrates the ability to heal fractures when administered locally as a single dose in rat models of fracture healing. CP-533536 demonstrates excellent in vitro potency against EP2 and selectivity against a broad panel of other targets.